• 一抗
  • 二抗
  • 慢病毒
  • 细胞系
  • 裂解物
  • 试剂类

Human ERBB2 Knockdown Cell Line (Wb-Validated) #C64611

一键复制产品信息
RT-qPCR analysis. HeLa cells were infected with ERBB2-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using gene-specific primers. ∆Ct (CtKD-CtWT) was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula: (1-1/2∆Ct) x 100%.
Western blotting analysis. ERBB2 protein expression in wild-type (WT) and shRNA knockdown (KD) HeLa cells was detected using Western blotting. Hsp90 α served as a loading control. The blots were incubated with primary antibodies against ERBB2 and Hsp90 α, respectively, followed by incubating with HRP-conjugated goat anti-rabbit secondary antibody. Images were developed using FeQ™ ECL Substrate Kit.
  • 基因名:
    ERBB2
  • 货号:
    C64611
  • 应用:
  • 物种反应性:
规格:
1 Kit
价格:
询价
Information
Product Name Human ERBB2 Knockdown Cell Line (Wb-Validated)
Aliases ERBB2; Erb-B2 Receptor Tyrosine Kinase 2; HER2; NEU; C-ERB-2; C-ERB2; MLN-19; HER-2; CD340; NGL; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; Tyrosine Kinase-Type Cell Surface Receptor HER2; Neuro/Glioblastoma Derived Oncogene Homolog; Human Epidermal Growth Factor Receptor 2; Receptor Tyrosine-Protein Kinase ErbB-2; Metastatic Lymph Node Gene 19 Protein; Proto-Oncogene C-ErbB-2; Proto-Oncogene Neu; P185(ErbB2); EC 2.7.10.1; MLN 19; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (Neuro/Glioblastoma Derived Oncogene Homolog); V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2; Neuroblastoma/Glioblastoma Derived Oncogene Homolog; Metastatic Lymph Node Gene 19; C-Erb B2/Neu Protein; CD340 Antigen; P185(ERBB2); HER-2/Neu; Herstatin; P185erbB2; EC 2.7.10; VSCN2; MLN19; TKR1
Background

Gene Name: ERBB2

NCBI Gene Entry: 2064

Storage Store at liquid nitrogen for 1 year.
Kit Components 1. Human ERBB2 Knockdown Cell Line (Wb-Validated)
2. Wild-type cell line
Parental Cell Line Human cell line supplied by the client
Validation Methods RT-qPCR, Western blotting (WB)
Shipping Shipped on Dry Ice.
Instructions For Use This knockdown cell line should be paired with wild-type cell line for use.
Note This product is for research use only.
Picture
  • RT-qPCR analysis. HeLa cells were infected with ERBB2-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using gene-specific primers. ∆Ct (CtKD-CtWT) was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula: (1-1/2∆Ct) x 100%.
  • Western blotting analysis. ERBB2 protein expression in wild-type (WT) and shRNA knockdown (KD) HeLa cells was detected using Western blotting. Hsp90 α served as a loading control. The blots were incubated with primary antibodies against ERBB2 and Hsp90 α, respectively, followed by incubating with HRP-conjugated goat anti-rabbit secondary antibody. Images were developed using FeQ™ ECL Substrate Kit.
Citation(0)
RT-qPCR analysis. HeLa cells were infected with ERBB2-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using gene-specific primers. ∆Ct (CtKD-CtWT) was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula: (1-1/2∆Ct) x 100%.
Western blotting analysis. ERBB2 protein expression in wild-type (WT) and shRNA knockdown (KD) HeLa cells was detected using Western blotting. Hsp90 α served as a loading control. The blots were incubated with primary antibodies against ERBB2 and Hsp90 α, respectively, followed by incubating with HRP-conjugated goat anti-rabbit secondary antibody. Images were developed using FeQ™ ECL Substrate Kit.
  • 联系电话

    0551-63635518

    0551-65578998

  • 联系邮箱

    support@genuinbiotech.cn

    sales@genuinbiotech.cn

微信公众号

Copyright © 2025 合肥善本生物科技有限公司

All Rights Reserved. 皖ICP备2023000814号